Company profile
TANGO THERAPEUTICS, INC.
NASDAQ:TNGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZOLDONRASIB | phase3 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06810544 | phase1_2 | recruiting | 2025-03-24 | 2027-03-31 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss |
| NCT05732831 | phase1_2 | recruiting | 2023-05-26 | 2027-06-01 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors |
| NCT05275478 | phase1_2 | terminated | 2022-03-23 | 2025-12-30 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors |
| NCT05887492 | phase1_2 | active_not_recruiting | 2023-06-12 | 2026-09-01 | Tango Therapeutics, Inc. | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
| NCT06065059 | phase1_2 | terminated | 2023-12-08 | 2024-05-22 | Tango Therapeutics, Inc. | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors |
FDA applications (0)
No records yet.